As previously reported, BofA analyst Allen Lutz upgraded Omnicell (OMCL) to Buy from Neutral with a price target of $70, up from $53, as the firm sees a significant upside revision cycle driven by the launch of Omnicell’s Titan XT product, its first new automated dispensing cabinet since 2017. The firm’s updated revenue and EBITDA estimates in 2027 and 2028 are 8% and 23% ahead of the Street, respectively, the analyst noted.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL:
- Omnicell upgraded to Buy from Neutral at BofA
- OMCL Earnings this Week: How Will it Perform?
- Omnicell price target raised to $60 from $50 at Benchmark
- Omnicell: Gradual Fundamental Improvement but Balanced Risk/Reward Supports Neutral (Hold) Rating
- KeyBanc upgrades Omnicell to Overweight ahead of ‘super-cycle’